Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients

Archives of Medical Science

Volumn 12, Issue 4, 2016, Pages 844-849

  Rysz Gorzynska, Magdalena ^a   Banach, MacIej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Chronic kidney disease; Dysfunctional HDL; High density lipoprotein (HDL); Subfractions

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DENSITY GRADIENT CENTRIFUGATION; ELECTROPHORETIC MOBILITY; HUMAN; INFLAMMATION; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION; PROTEIN MODIFICATION;

EID: 84977266813     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2016.60971     Document Type: Article

References (69)

1. Levey AS, de Jong PE, Coresh J, et al. The defnition, classifcation, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17-28.
2. Gluba-Brzózka A, Michalska-Kasiczak M, Franczyk B, et al. Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. Lipids Health Dis 2016; 15: 22.
3. Mahmoodi BK, Matsushita K, Woodward M, et al. Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380: 1649-61.
4. Chronic Kidney Disease Prognosis Consortium Association of estimated glomerular fltration rate and albu-minuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analy-sis. Lancet 2010; 375: 2073-81.
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
6. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. The glomerular fltration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007; 28: 478-83.
7. Franczyk-Skóra B, Gluba A, Olszewski R, Banach M, Rysz J. Clinical research: heart function disturbances in chronic kidney disease-echocardiographic indices. Arch Med Sci 2014; 10: 1109-6.
8. Thompson M, Ray U, Yu R, et al. Kidney function as a determinant of HDL and triglyceride concentrations in the Australian population. J Clin Med 2016; 5: pii: E35 doi: 10.3390/jcm5030035.
9. Chmielewski M, Carrero JJ, Nordfors L, Lindholm B, Sten-vinkel P. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol 2008; 21: 635-44.
10. Bowe B, Xie Y, Xian H, Balasubramanian S, Al-Aly Z. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int 2016; 89: 886-96.
11. Otocka-Kmiecik A, Mikhailidis D P, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51: 314-24.
12. Rysz J, Gluba-Brzózka A, Banach M, Wiecek A. Should we use statin in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge. Int Urol Nephrol 2015; 47: 805-13.
13. Banach M, Aronow WS, Serban MC, Rysz J, Voroneanu L, Covic A. Lipids, blood pressure and kidney update 2015. Lipids Health Dis 2015; 14: 167.
14. Colantonio LD, Baber U, Banach M, et al. Contrasting cholesterol management guidelines for adults with CKD. J Am Soc Nephrol 2015; 26: 1173-80.
15. Toth P P, Barylski M, Nikolic D, Rizzo M, Montalto G, Ban-ach M. Should low high-density lipoprotein cholesterol (HDL-C) be treated? Best Pract Res Clin Endocrinol Metab 2014; 28: 353-68.
16. Pownall H, Rosales C, Gillard B, Moon J, Gotto A. Human plasma lipoprotein metabolism. In: Clinical Lipidology: A companion to Braunwald's heart disease. 2nd ed. Bal-lantyne C (ed.). Philadelphia 2015; 3.
17. Dragan S, Serban C, Banach M. Can we change the functionality of HDL cholesterol with non-pharmacological and pharmacological agents? Curr Med Chem 2014; 21: 2927-46.
18. Asztalos, B F, Schaefer EJ. High-density lipoprotein sub-populations in pathologic conditions. Am J Cardiol 2003; 91: 12E-7E.
19. Toth P P, Barter PJ, Rosenson RS, et al. High-density lipo-proteins: a consensus statement from the National Lip-id Association. J Clin Lipidol 2013; 7: 484-525.
20. Weichhart T, Kopecky C, Kubicek M, et al. Serum amyloid A in uremic HDL promotes infammation. J Am Soc Nephrol 2012; 23: 934-47.
21. Skinner ER. High-density lipoprotein subclasses. Curr Opin Lipidol 1994; 5: 241-7.
22. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 1981; 22: 339-58.
23. Maeda S, Nakanishi S, Yoneda M, et al. Associations between small dense LDL, HDL subfractions (HDL2, HDL3) and risk of atherosclerosis in Japanese-Americans. J Ath-eroscler Thromb 2012; 19: 444-52.
24. Kasko M, Gaspar L, Dukát A, Gavorník P, Oravec S. High-density lipoprotein profile in newly-diagnosed lower extremity artery disease in Slovak population without diabetes mellitus. Neuro Endocrinol Lett 2014; 35: 531-5.
25. Farbstein D, Levy AP. HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther 2012; 10: 353-61.
26. Schaefer EJ, Santos RD, Asztalos BF. Marked HDL def-ciency and premature coronary heart disease. Curr Opin Lipidol 2010; 21: 289-97.
27. Rizzo M, Otvos J, Nikolic D, Montalto G, Toth P P, Ba-nach M. Subfractions and subpopulations of HDL: an update. Curr Med Chem 2014; 21: 2881-91.
28. Asztalos, B F, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Afairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005; 25: 2185-91.
29. Alaupovic P. The concept of apolipoprotein-defned lipo-protein families and its clinical signifcance. Curr Ath-eroscler Rep 2003; 5: 459-67.
30. Duriez P, Fruchart JC. High-density lipoprotein subclasses and apolipoprotein A-I. Clin Chim Acta 1999; 286: 97-114.
31. Dukát A, Oravec S, Wawruch M, Gavorník P, Sabaka P. The incidence of dyslipidemia in a sample of asymptomatic probands established by the means of Lipoprint system. Vnitr Lek 2011; 57: 258-60.
32. Oravec S, Dukat A, Gavornik P, et al. Atherogenic versus non-atherogenic lipoprotein profiles in healthy individuals. Is there a need to change our approach to diagnosing dyslipidemia? Curr Med Chem 2014; 21: 2892-901.
33. Musunuru K, Orho-Melander M, Caulfeld M P, et al. Ion mobility analysis of lipoprotein subfractions identifes three independent axes of cardiovascular risk. Arterio-scler Thromb Vasc Biol 2009; 29: 1975-80.
34. Otvos JD, Collins D, Freedman DS, et al. Low-density lipo-protein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfbrozil therapy in the Veterans Afairs High-Density Lipoprotein Intervention Trial. Circulation 2006; 113: 1556-63.
35. Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011; 57: 392-410.
36. Alabakovska SB, Todorova BB, Labudovic DD, Toshes-ka KN. LDL and HDL subclass distribution in patients with end-stage renal diseases. Clin Biochem 2002; 35: 211-6.
37. Soto-Miranda E, Carreón-Torres E, Lorenzo K, et al. Shift of high-density lipoprotein size distribution toward large particles in patients with proteinuria. Clin Chim Acta 2012; 414: 241-5.
38. Honda H, Hirano T, Ueda M, et al. High-density lipopro-tein subfractions and their oxidized subfraction particles in patients with chronic kidney disease. Atheroscler Thromb 2016; 23: 81-94.
39. Morgantini C, Natali A, Boldrini B, et al. Anti-infamma-tory and antioxidant properties of HDLs are impaired in type 2diabetes. Diabetes 2011; 60: 2617-23.
40. Lagos KG, Filippatos TD, Tsimihodimos V, et al. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids 2009; 44: 9-16.
41. McGillicuddy FC, de la Llera MM, Hinkle C, et al. Infam-mation impairs reverse cholesterol transport in vivo. Circulation 2009; 119: 1135-45.
42. Wang X, Rader DJ. Molecular regulation of macrophage reverse cholesterol transport Curr Opin Cardiol 2007; 22: 368-72.
43. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999; 14: 1462-6.
44. Serban C, Muntean D, Mikhailids D P, Toth P P, Banach M. Dysfunctional HDL: the journey from savior to slayer. Clin Lipidol 2014; 9: 49-59.
45. Yamamoto S, Yancey PG, Ikizler TA, et al. Dysfunctional high-density lipoprotein in patients on chronic hemodi-alysis. J Am Coll Cardiol 2012; 60: 2372-9.
46. Holzer M, Birner-Gruenberger R, Stojakovic T, et al. Uremia alters HDL composition and function. J Am Soc-Nephrol 2011; 22: 1631-41.
47. Kaseda R, Fazio S, Kon V. Chronic kidney disease (CKD) disruption of macrophage lipid handling and infamma-tion and Effect of liver X receptor (LXR) agonism. ASN Kidney Week 2014; 25: 869.
48. Nofer JR, Kehrel B, Fobker M, et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002; 161: 1-16.
49. Patel S, Di Bartolo BA, Nakhla S, et al. Anti-infammatory Effects of apolipoprotein A-I in the rabbit. Atherosclerosis 2010; 212: 392-7.
50. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Nav-ab M, Fogelman AM. Antiinfammatory properties of HDL. Circ Res 2004; 95: 764-72.
51. Navab M, Hama SY, Hough G P, Subbanagounder G, Red-dy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001; 42: 1308-17.
52. Weichhart T, Kopecky C, Kubicek M, et al. Serum amyloid A in uremic HDL promotes infammation. J Am Soc Nephrol 2012; 23: 934-47.
53. Toth PP. High-density lipoprotein: epidemiology, metabolism, and antiatherogenic Effects. Dis Mon 2001; 47: 369-416.
54. Podrez EA. Anti-oxidant properties of high-density lipo-protein and atherosclerosis. Clin Exp Pharmacol Physiol 2010; 37: 719-25.
55. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailid-is DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23: 370-8.
56. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495-508.
57. Van Lenten BJ, Reddy ST, Navab M, Fogelman AM. Understanding changes in high density lipoproteins during the acute phase response. Arterioscler Thromb Vasc Biol 2006; 26: 1687-8.
58. Kon V, Yang H, Fazio S. Residual cardiovascular risk in chronic kidney disease: role of high-density lipoprotein. Arch Med Res 2015; 46: 379-91.
59. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114: 529-41.
60. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired an-tioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 2009; 153: 77-85.
61. Kennedy DJ, Tang WH, Fan Y, et al. Diminished antioxi-dant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc 2013; 2: e000104.
62. Shao B, Oda MN, Oram J F, Heinecke JW. Myeloperoxi-dase: an infammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006; 21: 322-8.
63. Nofer JR, Brodde M F, Kehrel BE. High-density lipopro-teins, platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol 2010; 37: 726-35.
64. McGraw A P, Bagley J, Chen WS, et al. Aldosterone increases early atherosclerosis and promotes plaque in-fammation through a placental growth factor-dependent mechanism. J Am Heart Assoc 2013; 2: e000018.
65. Mineo C, Deguchi H, Grifn JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352-64.
66. Riwanto M, Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res 2013; 54: 3227-43.
67. Moody WE, Edwards NC, Madhani M, et al. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis 2012; 223: 86-94.
68. Speer T, Rohrer L, Blyszczuk P, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 2013; 38: 754-68.
69. Kontush A, Chapman MJ. Functionally dEffective HDL: a new therapeutic agent at the cross roads of dyslipid-emia, infammation and atherosclerosis. Pharmacol Rev 2006; 3: 342-74.